Teva, an importer of nutritional food compounds, filed a NIS 40 million lawsuit against Abbott

Teva, an importer of nutritional food compounds, filed a NIS 40 million lawsuit in Tel Aviv District Court against Abbott, an importer of infant food similac, and against the network's degrading agency and its CEO, Efrat Sela Itamar.
The lawsuit was filed claiming that Abbott had adopted a deceptive and deceptive advertising strategy with regard to Nutrilon products. In the lawsuit, Teva claims that Abbott utilized a Facebook network conversation following a technical change in the shape of the logo and transfer of Nutrilon production to a new factory in the Netherlands, "to embark on a large-scale, false, inciting and disguised campaign on social networks, among other things by running fictitious accounts and a large number of unpaid responders , Aimed at boosting and agitating a false and baseless discourse on the network, in which it is alleged that the formula of Nutrilon has been altered, so to speak, and that it causes infant morbidity. "
According to Teva, the incident occurred at the end of 2019. In the lawsuit, Teva claims that Abbott and Leeders used "a series of real mothers who, for payment or pleasure, spoke to the defendants' messages in Facebook, completing the praise of Similac, often imposing explicit notoriety on Nutrilone, In ugly and baseless insults. " Teva claims that she contacted Facebook to check the authenticity of several "suspicious" accounts, and Facebook confirmed her suspicions and removed some of the fictitious accounts.
Nutrilone importer claims the campaign against its brand has also been covered by media outlets and has led to brand injury. "The Nutrilone brand and its sales have suffered a significant loss estimated at millions of shekels."
Teva asks the court to charge the defendants NIS 34 million "for the severe damage to the Nutrilon brand and its reputation, for the considerable costs that Teva had to invest in its rehabilitation as a result of the defendants' actions and failures, and for the considerable impairment that occurred with Nutrilon's sales, while halting the growth trend ".
Alternatively, Teva requests that the defendants pay her "the maximum amount of compensation stipulated in the Prohibition Law as compensation without proof of damages, as stipulated in the Prohibition Law in respect of publications intended to damage a total of NIS 17.4 million." If it is not proven that the publications were made to harm Nutrilon, Teva would require Abbott to pay NIS 8.7 million, the maximum compensation provided by the Prohibition of Defamation Law as compensation without proof of damage. Teva also requires the defendants to "unlawfully reclaim their riches at her expense," in the amount of NIS 6 million and to issue an order prohibiting Abbott and Leeds from publishing any form of publicity against Neutrilon and Teva.
Efrat Sela Itamar, CEO of De Leaders, said "De Leaders has not yet received the lawsuit." Abbott has not yet commented.